Vimarsana
Biggest News Aggregation in the World

Page 13 - Beta Blocker News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Beta Blocker. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Beta Blocker Today - Breaking & Trending Today

Beta-Blockers May Not Improve Outcomes For Heart Attack Patients Without Cardiac Failure, Says Study - Vimarsana News

Beta-Blockers May Not Improve Outcomes For Heart Attack Patients Without Cardiac Failure, Says Study

Beta-blockers target beta receptors in the body that are responsible for increasing blood pressure.

Long term treatment with beta blockers may not be warranted in patients who don't have heart failure - Vimarsana News

Long term treatment with beta blockers may not be warranted in patients who don't have heart failure

The accepted clinical practice of using beta blockers over the long term to curb the risk of further heart attacks or death doesn't seem to be warranted in patients who don't have heart failure, suggests a large study published in the journal Heart.

Fatty Liver Diseases Treatment Market to Exhibit an Incredible Growth of USD 28 Billion by 2030, Size, Share, Trends, Key Drivers, Demand and Opportunity Analysis - Vimarsana News

Fatty Liver Diseases Treatment Market to Exhibit an Incredible Growth of USD 28 Billion by 2030, Size, Share, Trends, Key Drivers, Demand and Opportunity Analysis

Data Bridge Market Research completed a qualitative study titled "Fatty Liver Diseases Treatment Market" with 100+ market data tables, pie charts, graphs, and

Intensive blood pressure lowering by non-physician healthcare providers significantly reduces the risk of cardiovascular disease - Vimarsana News

Intensive blood pressure lowering by non-physician healthcare providers significantly reduces the risk of cardiovascular disease

1. A significant reduction in all-cause mortality was seen among patients in the intervention group compared to usual care. 2. Over 36 months, the net group difference in systolic blood pressure was -23.1 mmHg while the difference in diastolic blood pressure was -9.9 mmHg, favouring the intervention group. Evidence Rating Level: 1 (Excellent) Study Rundown:

Study shows how a specific gut microbe-generated byproduct is linked to heart failure risk - Vimarsana News

Study shows how a specific gut microbe-generated byproduct is linked to heart failure risk

New research at Cleveland Clinic expands the link between what we eat and how the gut microbiome impacts our susceptibility to develop different diseases – in this case, how a specific gut microbe-generated byproduct is linked to heart failure risk.